Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AMD comparison

AMD comparison

AMD comparison
Should ophthalmologists decide not to combine Macugen and Visudyne - a potential option and topic of discussion at last week's FDA panel meeting on Macugen - the absence of head-to-head data or a clear-cut clinical advantage for either compound could

Read the full 449 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers